Key Takeaways:
- The FDA is requiring Eli Lilly to conduct additional safety studies for Foundayo, including heart attack, stroke, and liver injury risks
- Foundayo was approved under the new fast-track priority voucher program weeks ago
- The FDA's requests are more extensive than those made for Novo Nordisk's oral Wegovy pill
- These post-approval safety requirements are routine for new medications and don't indicate immediate safety concerns
FDA Demands Additional Safety Data Just Weeks After Approval
The U.S. Food and Drug Administration has requested that Eli Lilly conduct additional safety studies for its newly approved GLP-1 weight loss pill Foundayo (orforglipron), according to the approval letter published online Tuesday. The request comes weeks after the drug received expedited approval under the agency's new Commissioner's National Priority Voucher program.
In the letter, the FDA said the data it has so far isn't enough to fully understand several potential risks tied to the drug, including heart problems such as heart attack and stroke, as well as drug-induced liver injuries. The agency is also seeking more information about delayed stomach emptying and thyroid cancer risks.
Foundayo was approved in early April 2026 under the FDA's Commissioner's National Priority Voucher, a pilot program intended to fast-track drug reviews. Issued 50 days after filing — and 294 days before the application's PDUFA date of January 20, 2027 — this decision represents a historic milestone as the first new molecular entity (NME) approved under the program. It is also the fastest approval of an NME since 2002.
What Makes This Safety Request Unusual
What's particularly noteworthy is the scope of the FDA's post-approval requirements for Foundayo compared to other recent GLP-1 approvals. In the approval letter for Novo Nordisk — the maker of the Wegovy pill — the FDA didn't ask the company for additional data on liver or heart problems or thyroid cancer.
The FDA is specifically asking Lilly to collect data on several areas of concern:
- Cardiovascular risks including heart attack and stroke
- Drug-induced liver injuries
- Delayed gastric emptying (when food remains in the stomach too long)
- Thyroid cancer risk monitoring for at least 15 years
Injectable GLP-1s, like Wegovy and Zepbound, carry an FDA boxed warning about a rare risk of thyroid cancer. The agency is also asking Lilly to collect data on thyroid cancer risk for at least 15 years.
Clinical Context: Why These Concerns Matter
As the first small-molecule GLP-1 receptor agonist to gain approval, orforglipron offers a potential convenience edge over established peptidic GLP-1-based obesity drugs. However, this novel mechanism may also present unique safety considerations that weren't fully apparent in clinical trials.
Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina, provided important context about these requests. "It doesn't mean a safety problem has been found. It means they want more definitive long-term data," McGowan said. He noted that "with orforglipron, it's a newer, non-peptide version of a GLP-1, so we don't yet have the same depth of safety data as the injectables."
This distinction is important when comparing Foundayo to other established GLP-1 medications like semaglutide and tirzepatide, which have longer track records in clinical practice.
In clinical trials, Foundayo demonstrated meaningful weight loss results. In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight –- about 25 pounds on average –- over more than 16 months. That compared with a 2.1% weight loss, or less than 5 pounds, in patients who received a placebo.
The trial data also showed side effects consistent with other GLP-1 medications, including nausea, vomiting, and diarrhea. However, the long-term cardiovascular and liver effects that the FDA is now requesting data on weren't fully evaluated during the approval process due to the expedited timeline.
Industry Response and Market Impact
Lilly has responded to the FDA's requirements with reassurance about their commitment to ongoing safety monitoring. A Lilly spokesperson said in an emailed statement that the FDA's post-approval requirements are routine and consistent with the agency's approach to ongoing safety reviews of newly approved drugs. "Patient safety is Lilly's top priority and we actively monitor, evaluate, and report safety information for all our medicines," the spokesperson said.
Foundayo is currently available through LillyDirect and retail pharmacies with pricing starting at $149 per month for cash-paying patients and as low as $25 monthly for those with qualifying commercial insurance. The drug is also included in the Medicare GLP-1 Bridge program, which will make it available to eligible beneficiaries starting July 1, 2026.
Despite the FDA's additional requirements, analysts don't expect immediate market disruption. The drug remains on the market and available to prescribers while these studies are conducted. For people exploring their options, understanding how Foundayo's pricing compares to other treatments can help inform decisions—you can explore various cost comparison options to understand pricing across different providers and insurance scenarios.
What This Means for You
If you're considering Foundayo or currently taking it, these FDA requests shouldn't cause immediate alarm. The agency routinely requires additional safety monitoring for newly approved medications, especially those with novel mechanisms of action. However, it's important to discuss any concerns with your healthcare provider and be aware of potential warning signs the FDA is monitoring.
Here are key points to keep in mind:
If you're currently taking Foundayo: Continue your prescribed regimen but stay alert for symptoms like chest pain, unusual fatigue, abdominal pain, or changes in your thyroid area. Report any concerning symptoms to your healthcare provider promptly.
If you're considering starting Foundayo: Discuss the benefits and risks with your provider, including how this newer medication compares to established options with longer safety track records.
For all GLP-1 users: Remember that these medications work best as part of a comprehensive approach that includes lifestyle changes. The convenience of an oral medication like Foundayo may appeal to many people, but the choice between different GLP-1 medications should be made based on your individual health profile and risk factors.
Working with experienced providers who stay current on the latest safety data and can help you weigh the benefits and risks of different treatments is more important than ever as new options enter the market.
Sources
- FDA asks Lilly for more safety data on weight loss pill Foundayo - NBC News report on FDA's post-approval safety requirements
- FDA Approves First New Molecular Entity Under National Priority Voucher Program - Official FDA press announcement
- Medicare GLP-1 Bridge - CMS information on Medicare coverage
- FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity - PBS NewsHour background on approval